Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Bayer is paying Mammoth Biosciences $40 million upfront and up to $1 billion in milestones to develop in vivo gene therapies using the biotech's ultra-compact…
Bayer is partnering with Mammoth Biosciences, the CRISPR startup co-founded by Jennifer Doudna, to develop in vivo gene-editing therapies using miniature Cas…
Mammoth's first development candidate MB-111 leverages CasPhi, a proprietary ultracompact CRISPR nuclease, delivered by LNP to disrupt APOC3 in the liver as a…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Bayer and Mammoth Biosciences entered a strategic collaboration and option agreement leveraging Mammoth's ultra-small Cas enzymes (Cas14, Cas-phi) for in vivo gene-editing therapies across five preselected indications. Mammoth received $40M upfront and is eligible for option exercise fees plus over $1B in milestones. Review (June 2026): no primary source indicates the collaboration has closed or terminated; as of 2025 Mammoth still listed Bayer among its active partnerships (alongside Vertex and Regeneron). The underlying ultracompact platform has advanced materially since signing — Mammoth reported new NanoCas extrahepatic-editor results (Jan 2025) and nominated its first development candidate, MB-111, a CasPhi-based, LNP-delivered in vivo liver editor targeting APOC3 for persistent chylomicronemia, with preclinical data at ESGCT (Oct 2025) and a planned clinic entry in 2026 — reinforcing the deal's ultra-compact / liver-targeted thesis. (MB-111 is not attributed by Mammoth to the Bayer collaboration specifically.)
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Mammoth Biosciences Inc. (this deal) | 2022 | $1.0B | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2022 deals · Bayer AG deals · Gastroenterology deals